News

D-Pharm announced that it has received FDA approval for its Investigational New Drug (IND) application for a pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke

PDX and Rx.com have entered into a strategic agreement with Microsoft to make prescription data, which Rx.com manages for multiple chain and independent pharmacy clients, available to Microsoft

iMedica Corporation, a leading developer of healthcare software solutions for physician practices, announced that after more than two years of research and consideration, the Physicians’ Organization of the

Millipore expects the new facility will employ 120 before the end of 2009. The company currently employs over 1,000 in Massachusetts and almost 6,000 around the world. Millipore’s

The VerifyNow System assesses response to antiplatelet therapies, such as aspirin, Plavix and GP IIb/IIIa inhibitors. As response to these drugs varies, the tests help physicians ensure their

Progenics has announced the discontinuation of the development program for PRO 206, a pre-clinical compound for the treatment of hepatitis-C virus (HCV) infection. The decision was made as

Merck has presented new data at the American Diabetes Association (ADA’) 69th Annual Scientific Sessions. It showed that initial treatment with JANUMET (sitagliptin/metformin) provided greater blood sugar improvements

ISTA has declared positive results for Phase-II clinical study in subjects with dry eye disease (keratoconjuctivitis sicca). The company used its proprietary, low-dose formulation of bromfenac, the active

Progenics and Ono Pharmaceutical announced that they have started clinical testing of RELISTOR (methylnaltrexone bromide) subcutaneous injection in Japan. Its the first in class medicine approved in the